

# Brent R Logan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4537250/publications.pdf>

Version: 2024-02-01

163  
papers

8,891  
citations

53660

45  
h-index

46693

89  
g-index

167  
all docs

167  
docs citations

167  
times ranked

9243  
citing authors

#	ARTICLE	IF	CITATIONS
1	Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. <i>New England Journal of Medicine</i> , 2012, 367, 1487-1496.	13.9	762
2	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. <i>Blood</i> , 2014, 123, 3664-3671.	0.6	730
3	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009. <i>New England Journal of Medicine</i> , 2014, 371, 434-446.	13.9	594
4	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2017, 35, 1154-1161.	0.8	495
5	Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 1273-1283.	0.8	281
6	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	5.1	263
7	Analyzing survival curves at a fixed point in time. <i>Statistics in Medicine</i> , 2007, 26, 4505-4519.	0.8	256
8	Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 454-459.	2.0	256
9	Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study. <i>Blood</i> , 2017, 130, 2718-2727.	0.6	212
10	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , the, 2019, 6, e132-e143.	2.2	200
11	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377.	0.6	178
12	A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016, 128, 2561-2567.	0.6	174
13	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1479-1487.	2.0	173
14	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. <i>Blood</i> , 2018, 132, 1737-1749.	0.6	128
15	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 359-370.	2.0	127
16	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	0.6	119
17	Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. <i>Blood</i> , 2014, 123, 3655-3663.	0.6	112
18	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation. <i>JAMA Oncology</i> , 2016, 2, 1583.	3.4	110

#	ARTICLE	IF	CITATIONS
19	An evaluation of thresholding techniques in fMRI analysis. <i>NeuroImage</i> , 2004, 22, 95-108.	2.1	109
20	The Natural History of Children with Severe Combined Immunodeficiency: Baseline Features of the First Fifty Patients of the Primary Immune Deficiency Treatment Consortium Prospective Study 6901. <i>Journal of Clinical Immunology</i> , 2013, 33, 1156-1164.	2.0	100
21	Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1049-1056.	2.0	98
22	Nonparametric survival analysis using Bayesian Additive Regression Trees (BART). <i>Statistics in Medicine</i> , 2016, 35, 2741-2753.	0.8	95
23	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	0.6	92
24	National Marrow Donor Programâ€“Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2021, 39, 1971-1982.	0.8	90
25	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1183-1189.	2.0	89
26	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. <i>Blood</i> , 2020, 135, 2094-2105.	0.6	87
27	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitorâ€“Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2022, 40, 356-368.	0.8	79
28	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 858-864.	2.0	78
29	Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1530-1536.	2.0	78
30	Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. <i>Journal of Clinical Oncology</i> , 2014, 32, 2365-2372.	0.8	77
31	Observational Studies: Matching or Regression?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 557-563.	2.0	76
32	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics postâ€“allogeneic HCT. <i>Blood</i> , 2017, 129, 162-170.	0.6	75
33	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339.	0.8	72
34	Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 142-150.	2.0	66
35	Primary Immune Deficiency Treatment Consortium (PIDTC) report. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 335-347.e11.	1.5	65
36	The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 405-407.	1.5	64

#	ARTICLE	IF	CITATIONS
37	Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients. <i>Clinical Cancer Research</i> , 2016, 22, 69-78.	3.2	63
38	Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. <i>Blood</i> , 2015, 126, LBA-8-LBA-8.	0.6	59
39	Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020, 189, 1171-1181.	1.2	58
40	Comparing Treatments in the Presence of Crossing Survival Curves: An Application to Bone Marrow Transplantation. <i>Biometrics</i> , 2008, 64, 733-740.	0.8	57
41	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. <i>Frontiers in Immunology</i> , 2020, 11, 239.	2.2	57
42	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020, 135, 97-107.	0.6	56
43	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, 1426-1433.	1.7	53
44	Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation. <i>Journal of Clinical Oncology</i> , 2015, 33, 364-369.	0.8	51
45	Deep Reinforcement Learning for Dynamic Treatment Regimes on Medical Registry Data. , 2017, 2017, 380-385.		49
46	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1274-1280.	2.0	46
47	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1308-1314.	2.0	45
48	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1440-1448.	2.0	44
49	Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. <i>American Journal of Neuroradiology</i> , 2018, 39, 1008-1016.	1.2	43
50	Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. <i>Journal of Clinical Immunology</i> , 2019, 39, 653-667.	2.0	41
51	The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. <i>Blood</i> , 2019, 133, 754-762.	0.6	40
52	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome. <i>JAMA Oncology</i> , 2020, 6, 486.	3.4	39
53	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. <i>Blood Advances</i> , 2020, 4, 467-476.	2.5	39
54	Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 107-112.	2.0	38

#	ARTICLE	IF	CITATIONS
55	Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression. <i>Blood</i> , 2016, 128, 2068-2082.	0.6	38
56	ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 746-754.	2.0	37
57	B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. <i>Blood</i> , 2018, 131, 2967-2977.	0.6	37
58	Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 2250-2263.	2.5	37
59	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021, 41, 38-50.	2.0	36
60	Multiple Test Procedures for Identifying the Minimum Effective and Maximum Safe Doses of a Drug. <i>Journal of the American Statistical Association</i> , 2002, 97, 293-301.	1.8	35
61	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 55-59.	2.0	34
62	A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018, 103, 1915-1924.	1.7	34
63	An evaluation of spatial thresholding techniques in fMRI analysis. <i>Human Brain Mapping</i> , 2008, 29, 1379-1389.	1.9	33
64	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. <i>Bone Marrow Transplantation</i> , 2020, 55, 906-917.	1.3	33
65	Marginal Models for Clustered Time-to-Event Data with Competing Risks Using Pseudovalues. <i>Biometrics</i> , 2011, 67, 1-7.	0.8	32
66	Decision making and uncertainty quantification for individualized treatments using Bayesian Additive Regression Trees. <i>Statistical Methods in Medical Research</i> , 2019, 28, 1079-1093.	0.7	32
67	Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors. <i>American Journal of Neuroradiology</i> , 2019, 40, 626-633.	1.2	30
68	Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 333-342.	2.0	30
69	Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2040-2046.	2.0	29
70	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018, 18, 593.	1.1	28
71	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
72	Race and Ethnicity Influences Collection of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 165-171.	2.0	26

#	ARTICLE	IF	CITATIONS
73	Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1108-1116.	2.0	26
74	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 507-516.	0.6	26
75	Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. <i>Blood</i> , 2022, 140, 685-705.	0.6	26
76	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1566-1572.	2.0	24
77	Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. <i>Blood</i> , 2011, 118, 1-1.	0.6	24
78	Use of biological assignment in hematopoietic stem cell transplantation clinical trials. <i>Clinical Trials</i> , 2008, 5, 607-616.	0.7	21
79	European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 514-519.	2.0	21
80	Pairwise multiple comparison adjustment in survival analysis. <i>Statistics in Medicine</i> , 2005, 24, 2509-2523.	0.8	20
81	Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2256-2263.	2.0	20
82	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012, 120, 739-739.	0.6	19
83	A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7075-TPS7075.	0.8	17
84	Analyzing center specific outcomes in hematopoietic cell transplantation. <i>Lifetime Data Analysis</i> , 2008, 14, 389-404.	0.4	16
85	Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 688-695.	2.0	16
86	Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. <i>JAMA Oncology</i> , 2020, 6, e192974.	3.4	15
87	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.	2.0	14
88	Nonparametric competing risks analysis using Bayesian Additive Regression Trees. <i>Statistical Methods in Medical Research</i> , 2020, 29, 57-77.	0.7	14
89	Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 494-507.	1.0	14
90	Accurate Critical Constants for the One-Sided Approximate Likelihood Ratio Test of a Normal Mean Vector When the Covariance Matrix Is Estimated. <i>Biometrics</i> , 2002, 58, 650-656.	0.8	13



#	ARTICLE	IF	CITATIONS
91	Superiority Inferences on Individual Endpoints Following Noninferiority Testing in Clinical Trials. <i>Biometrical Journal</i> , 2008, 50, 693-703.	0.6	13
92	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
93	Learning the Dynamic Treatment Regimes from Medical Registry Data through Deep Q-network. <i>Scientific Reports</i> , 2019, 9, 1495.	1.6	13
94	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019, 104, 844-854.	1.7	13
95	Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. <i>JCO Precision Oncology</i> , 2021, 5, 265-274.	1.5	13
96	The use of group sequential designs with a common competing risks tests. <i>Statistics in Medicine</i> , 2013, 32, 899-913.	0.8	12
97	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838.	2.0	12
98	On O'Brien's OLS and GLS tests for multiple endpoints. <i>Lecture Notes-monograph Series / Institute of Mathematical Statistics</i> , 2004, , 76-88.	1.0	12
99	Review of Multistate Models in Hematopoietic Cell Transplantation Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S84-S87.	2.0	11
100	Quality of Life of Patients with Wiskott Aldrich Syndrome and X-Linked Thrombocytopenia: a Study of the Primary Immune Deficiency Consortium (PIDTC), Immune Deficiency Foundation, and the Wiskott-Aldrich Foundation. <i>Journal of Clinical Immunology</i> , 2019, 39, 786-794.	2.0	11
101	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
102	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. <i>Blood</i> , 2015, 126, 193-193.	0.6	11
103	The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively Discriminate Risks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases. <i>Blood</i> , 2012, 120, 737-737.	0.6	11
104	Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 161-164.	2.0	10
105	Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1780-1788.	1.3	10
106	Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 745-757.	2.0	10
107	Comorbidity Index (CI) in Autologous Hematopoietic Cell Transplantation (HCT) for Malignant Diseases: Validation of the HCT-CI. <i>Blood</i> , 2012, 120, 814-814.	0.6	10
108	Optimal two-stage randomized phase II clinical trials. <i>Clinical Trials</i> , 2005, 2, 5-12.	0.7	8

#	ARTICLE	IF	CITATIONS
109	Statistical Methods for Time-Dependent Variables in Hematopoietic Cell Transplantation Studies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 125-132.	0.6	8
110	Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Blood</i> , 2014, 124, 206-206.	0.6	8
111	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
112	Regarding "Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study" <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e268-e269.	2.0	7
113	Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 955-964.	2.0	7
114	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 2121-2131.	1.3	7
115	Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e142-e144.	2.0	7
116	5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood. <i>Blood</i> , 2015, 126, 270-270.	0.6	7
117	A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models. <i>Statistics in Medicine</i> , 2021, 40, 1121-1132.	0.8	6
118	Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 650-657.	0.6	6
119	Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2014, 124, 422-422.	0.6	6
120	Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7571-7571.	0.8	6
121	A cone order monotone test for the one-sided multivariate testing problem. <i>Statistics and Probability Letters</i> , 2003, 63, 315-323.	0.4	5
122	Group sequential tests for long-term survival comparisons. <i>Lifetime Data Analysis</i> , 2015, 21, 218-240.	0.4	5
123	A cure-rate model for Q&learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients. <i>Biometrical Journal</i> , 2019, 61, 442-453.	0.6	5
124	Larger Numbers of Donor Naïve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201. <i>Blood</i> , 2011, 118, 1004-1004.	0.6	5
125	A Multicenter Phase II Trial of Unrelated Donor Reduced Intensity Bone Marrow Transplantation for Children with Severe Sickle Cell Disease (SCURT): Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0601) Study. <i>Blood</i> , 2015, 126, 619-619.	0.6	5
126	Phase II trial using haploidentical hematopoietic cell transplantation (HCT) followed by donor natural killer (NK) cell infusion and sirolimus maintenance for patients with high-risk solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23551-e23551.	0.8	5



#	ARTICLE	IF	CITATIONS
127	Pseudo-value approach for conditional quantile residual lifetime analysis for clustered survival and competing risks data with applications to bone marrow transplant data. <i>Annals of Applied Statistics</i> , 2016, 10, 618-637.	0.5	4
128	Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a <scp>BMT CTN</scp> 0102 correlative study. <i>British Journal of Haematology</i> , 2017, 178, 816-819.	1.2	4
129	A Group Sequential Test for Treatment Effect Based on the Fineâ€“Gray Model. <i>Biometrics</i> , 2018, 74, 1006-1013.	0.8	4
130	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.	2.0	4
131	Use of Peripheral Blood Grafts Is Associated with Increased Acute and Chronic Graft-Versus-Host Disease without Improved Survival after Unrelated Donor Transplantation.. <i>Blood</i> , 2005, 106, 443-443.	0.6	4
132	Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays â€“ Comparison with Electrophoretic Responses in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 2877-2877.	0.6	4
133	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. <i>Blood</i> , 2012, 120, 733-733.	0.6	4
134	The Likelihood of Hematopoietic Stem Cell Transplantation (HCT) in the United States: Implications for Umbilical Cord Blood Storage.. <i>Blood</i> , 2005, 106, 1330-1330.	0.6	4
135	Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic. <i>Blood</i> , 2021, 138, 2846-2846.	0.6	4
136	Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 406.e1-406.e6.	0.6	4
137	Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians. <i>Leukemia and Lymphoma</i> , 2022, 63, 2507-2510.	0.6	4
138	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab441.	0.4	3
139	Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 34-35.	0.6	3
140	BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD). <i>Blood</i> , 2008, 112, 55-55.	0.6	3
141	Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , 2013, 122, 1687-1687.	0.6	3
142	Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicular Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701). <i>Blood</i> , 2014, 124, 682-682.	0.6	3
143	Psychosocial services for primary immunodeficiency disorder families during hematopoietic cell transplantation: A descriptive study. <i>Palliative and Supportive Care</i> , 2019, 17, 409-414.	0.6	2
144	Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 503.e1-503.e8.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. Transplantation and Cellular Therapy, 2021, 27, 352.e1-352.e5.	0.6	2
146	BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). Blood, 2019, 134, 1955-1955.	0.6	2
147	CFU-GM Assay Can Be Predictive of Umbilical Cord Blood Engraftment.. Blood, 2006, 108, 5212-5212.	0.6	2
148	Reducing the Risk for Transplant Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?.. Blood, 2009, 114, 649-649.	0.6	2
149	Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT).. Blood, 2010, 116, 3486-3486.	0.6	2
150	Excellent Outcomes After Umbilical Cord Blood Transplantation Using a Centralized Cord Blood Registry. Stem Cells Translational Medicine, 2018, 7, S1-S1.	1.6	1
151	Testing for center effects on survival and competing risks outcomes using pseudo-value regression. Lifetime Data Analysis, 2019, 25, 206-228.	0.4	1
152	Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point. Lifetime Data Analysis, 2020, 26, 603-623.	0.4	1
153	COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum. Transplantation and Cellular Therapy, 2021, 27, 533-539.	0.6	1
154	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201. Blood, 2021, 138, 1772-1772.	0.6	1
155	Phenyl N-Tert-Butylnitron (PBN) Protects Syngeneic Marrow Transplant Recipients from the Lethal Cytokine Syndrome Occurring after Agonistic CD40 Antibody Administration.. Blood, 2004, 104, 2128-2128.	0.6	0
156	Peripheral Blood Stem Cell (PBSC) Donors Experience Higher Levels of Pain and Toxicities Early On, While Bone Marrow (BM) Donors Experience Slower Recovery and More Late Pain: A Prospective Study of the National Marrow Donor Program (NMDP).. Blood, 2010, 116, 1107-1107.	0.6	0
157	Survival Of AML Patients Relapsing After Allogeneic Stem Cell Transplantation: A Center For International Blood and Marrow Transplant Research Study. Blood, 2013, 122, 2072-2072.	0.6	0
158	Baseline Symptoms, Female Sex, and Younger Age Are Correlated with Higher Levels of Peri-Collection Pain, Symptoms, and Persistent Discomfort One Year after Related Donor BM and PBSC Donation: An Analysis of the Related Donor Safety Study (RDSafe). Blood, 2014, 124, 3847-3847.	0.6	0
159	Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Immune (1801). Blood, 2019, 134, 2005-2005.	0.6	0
160	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood, 2020, 136, 7-8.	0.6	0
161	Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). Blood, 2020, 136, 33-34.	0.6	0
162	BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). Blood, 2020, 136, 40-41.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 7-8.	0.6	0